Meeting
2012 ASCO Annual Meeting
Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).
Authors
Cynthia R. C. Osborne
Baylor Sammons Cancer Center, Texas Oncology PA, US Oncology, Dallas, TX
Cynthia R. C. Osborne , Joyce O'Shaughnessy , Frankie Ann Holmes , Hyun Sue Kim , Darren M. Kocs , Michael S. Steinberg , Paul D. Richards , Svetislava J. Vukelja , Noah C. Berkowitz , Aby Buchbinder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT01036113
Citation
J Clin Oncol 30, 2012 (suppl; abstr 1017)
DOI
10.1200/jco.2012.30.15_suppl.1017
Abstract #
1017
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.
First Author: Lee S. Schwartzberg
Poster
2014 ASCO Annual Meeting
Phase II study of pseudomonas aeruginosa-mannose-sensitive hemagglutinin in combination with capecitabine for HER2-negative metastatic breast cancer pretreated with anthracycline and taxane.
First Author: Fangfang Lv
Poster
2012 ASCO Annual Meeting
WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes.
First Author: Toshimi Takano
Poster
2023 ASCO Annual Meeting
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial.
First Author: Min Yan